Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of N-Acetyl-L-Leucine on CACNA1A Disorders: A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study

NCT07221292 is registered in ClinicalTrials.gov with IntraBio Inc as lead sponsor.

NCT NCT07221292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07221292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of N-Acetyl-L-Leucine on CACNA1A Disorders: A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study
Lead sponsor
IntraBio Inc
Phase
Phase 3
Overall status
Recruiting
Start date
August 17, 2026
Completion date
November 1, 2028
Enrollment
60 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cacna1a, episodic ataxia type 2, familial hemiplegic migraine-1, spinocerebellar ataxia type 6